Latest European Markets News

Adveritas Limited reports a robust 62% increase in annualised recurring revenue to $10.47 million and a record doubling of full-year cash receipts, backed by a strategic $8.5 million institutional placement to accelerate growth in the US and new verticals.

International Graphite Limited is advancing its strategy to become a global mine-to-market industrial graphite company, with a new joint venture in Germany and expansion of its Western Australian operations targeting production by 2027.

International Graphite Limited (ASX – IG6) has had its trading suspension lifted following the announcement of a new agreement to develop a graphite processing facility in Europe.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

European Lithium has sold 0.5 million shares of Critical Metals Corp for US$1.625 million, underscoring the substantial value of its remaining CRML stake, now valued at approximately US$205 million.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.